Guo Ti, Wang Yadong
Hubei Cancer Hospital,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430079, Hubei, China.
Wuhan Hospital of Traditional Chinese Medicine, Wuhan, 430014, Hubei, China.
Appl Biochem Biotechnol. 2024 Nov;196(11):8282-8305. doi: 10.1007/s12010-024-04957-9. Epub 2024 May 10.
Colon cancer (CC) is a malignant tumor in the colon. Despite some progress in the early detection and treatment of CC in recent years, some patients still experience recurrence and metastasis. Therefore, it is urgent to better predict the prognosis of CC patients and identify new biomarkers. Recent studies have shown that anoikis-related genes (ARGs) play a significant role in the progression of many tumors. Hence, it is essential to confirm the role of ARGs in the development and treatment of CC by integrating scRNA-seq and transcriptome data. This study integrated transcriptome and single-cell sequencing (scRNA-seq) data from CC samples to evaluate patient stratification, prognosis, and ARG expression in different cell types. Specifically, differential expression of ARGs was identified through consensus clustering to classify CC subtypes. Subsequently, a CC risk model composed of CDKN2A, NOX4, INHBB, CRYAB, TWIST1, CD36, SERPINE1, and MMP3 was constructed using prognosis-related ARGs. Finally, using scRNA-seq data of CC, the expression landscape of prognostic genes in different cell types and the relationship between important immune cells and other cells were explored. Through the above analysis, two CC subtypes were identified, showing significant differences in prognosis and clinical factors. Subsequently, a risk model comprising aforementioned genes successfully categorized all CC samples into two risk groups, which also exhibited significant differences in prognosis, clinical factors, involved pathways, immune landscape, and drug sensitivity. Multiple pathways (cell adhesion molecules (CAMs), and extracellular matrix (ECM) receptor interaction) and immune cells/immune functions (B cell naive, dendritic cell activate, plasma cells, and T cells CD4 memory activated) related to CC were identified. Furthermore, it was found that prognostic genes were highly expressed in various immune cells, and B cells exhibited more and stronger interaction pathways with other cells. The results of this study may provide references for personalized treatment and potential biomarker identification in CC.
结肠癌(CC)是结肠中的一种恶性肿瘤。尽管近年来CC的早期检测和治疗取得了一些进展,但仍有一些患者会出现复发和转移。因此,迫切需要更好地预测CC患者的预后并识别新的生物标志物。最近的研究表明,失巢凋亡相关基因(ARGs)在许多肿瘤的进展中发挥着重要作用。因此,通过整合单细胞RNA测序(scRNA-seq)和转录组数据来确认ARGs在CC发生发展和治疗中的作用至关重要。本研究整合了CC样本的转录组和单细胞测序(scRNA-seq)数据,以评估患者分层、预后以及不同细胞类型中ARGs的表达。具体而言,通过一致性聚类确定ARGs的差异表达,以对CC亚型进行分类。随后,使用与预后相关的ARGs构建了一个由CDKN2A、NOX4、INHBB、CRYAB、TWIST1、CD36、SERPINE1和MMP3组成的CC风险模型。最后,利用CC的scRNA-seq数据,探索了不同细胞类型中预后基因的表达情况以及重要免疫细胞与其他细胞之间的关系。通过上述分析,确定了两种CC亚型,它们在预后和临床因素方面存在显著差异。随后,一个包含上述基因的风险模型成功地将所有CC样本分为两个风险组,这两个风险组在预后、临床因素、涉及的通路、免疫图谱和药物敏感性方面也表现出显著差异。确定了与CC相关的多个通路(细胞粘附分子(CAMs)和细胞外基质(ECM)受体相互作用)以及免疫细胞/免疫功能(B细胞幼稚型、树突状细胞活化型、浆细胞和T细胞CD4记忆活化型)。此外,发现预后基因在各种免疫细胞中高表达,并且B细胞与其他细胞表现出更多更强的相互作用通路。本研究结果可能为CC的个性化治疗和潜在生物标志物的识别提供参考。